Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

9.400 USD -0.160 (-1.67%)
Streaming Delayed Price Updated: 4:49 AM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Inovio Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
INOVIO Announces Proposed Public Offering of Common Stock
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including... 
From PR Newswire
4 Hot NASDAQ Stocks: Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: RIOT)
Tags Investingcom MARA JAGX
From OTC
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment 
From PR Newswire
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
Partnership Adds Asian Manufacturing Resource to INOVIO's Global Manufacturing Consortium for INO-4800 
From PR Newswire
Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp?
InvestorsObserver issues critical PriceWatch Alerts for GEVO, INO, ODT, COCP, and VUZI. 
From PR Newswire
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses 
From PR Newswire
Optimism Building As Additional COVID-19 Vaccines Are Expected to be Released Globally
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Optimism Building As Additional COVID-19 Vaccines Are Expected to be Released Globally
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?
InvestorsObserver issues critical PriceWatch Alerts for TCRR, INO, BLRX, PLUG, and ABUS. 
From PR Newswire
INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Joi
- DARPA to fund innovative public-private partnership between INOVIO, The Wistar Institute, AstraZeneca, the University of Pennsylvania and Indiana University 
From PR Newswire
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
Dosing marks a key milestone for INO-4800 in China and its second Phase 2 clinical trial globally 
From PR Newswire
How Acute Respiratory Distress Syndrome (ARDS) May Be Affecting COVID-19 Patients
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
How Acute Respiratory Distress Syndrome (ARDS) May Be Affecting COVID-19 Patients
Financialnewsmedia.com News Commentary 
From PR Newswire
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
DNA immunotherapy candidate VGX-3100 demonstrated resolution of HPV-16/18-associated precancerous anal lesions in 50% of treated patients six months after treatment 
From PR Newswire
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has... 
From PR Newswire
Thinking about buying stock in Sutro Biopharma, BioCryst Pharmaceuticals, Inovio Pharmaceuticals, Cocrystal Pharma, or Clean Energy Fuels?
InvestorsObserver issues critical PriceWatch Alerts for STRO, BCRX, INO, COCP, and CLNE. 
From PR Newswire
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
Partnership with leading global plasmid manufacturer advances INOVIO's INO-4800 
From PR Newswire
InvestorNewsBreaks – A Glimpse into Robinhood’s 100 Most Popular Stocks
From InvestorBrandNetwork
Thinking about buying stock in AMC Entertainment, Inovio Pharmaceuticals, Sundial Growers, Nikola Corp, or Sorrento Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for AMC, INO, SNDL, NKLA, and SRNE. 
From PR Newswire
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has... 
From PR Newswire
Thinking about trading options or stock in Pfizer, Inovio Pharmaceuticals, Alibaba, General Electric, or Nio?
InvestorsObserver issues critical PriceWatch Alerts for PFE, INO, BABA, GE, and NIO. 
From PR Newswire
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at
Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients 
From PR Newswire
Vitally Important COVID-19 Test Kit Market Could Exceed $15 Billion This Year Alone
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Vitally Important COVID-19 Test Kit Market Could Exceed $15 Billion This Year Alone
FinancialNewsMedia.com News Commentary 
From PR Newswire
Thinking about buying stock in Pfizer, Moderna, Inovio Pharmaceuticals, AMC Entertainment, or HighPoint Resources?
InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, INO, AMC, and HPR. 
From PR Newswire
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has... 
From PR Newswire
More Comprehensive Diagnostics are Needed as Cases Surge Once More
FinancialBuzz.com News Commentary 
From PR Newswire
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments
Financialnewsmedia.com News Commentary 
From PR Newswire
INOVIO Reports Third Quarter 2020 Financial Results
Investor Call Today at 4:30 PM ET 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.